BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery – Reducing Time, Cost, & Late Stage Attrition of Drug Candidates
Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery - Reducing Time, Cost, & Late Stage Attrition of Drug Candidates

Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery – Reducing Time, Cost, & Late Stage Attrition of Drug Candidates

June 16, 2016 By Cade Hildreth (CEO) Leave a Comment

Pluriomics is a Dutch company that specializes in the “production and industrialization of high-quality, fully functional hiPS cells-derived cardiovascular cell types and on the development and realization of electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology, toxicology testing and efficacy screening.”

Discover class-defining bioproduction tools.

In news released today, the company announced that it will receive a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery.

The company also announced last month that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development.

bitbio

To learn more about the €3.2M grant under the Horizon 2020 SME instrument programme, read the full press release below, printed with permission from Celine Hechard, PhD, VP Business Development & Marketing at Pluriomics.


Pluriomics receives a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery

Leiden, June 16, 2016 – Pluriomics, an emerging Dutch/Belgian biotechnology company whose mission is to deliver innovative human cardiomyocyte assays for use in drug discovery & development, today announced it was awarded a prestigious EU SME instrument grant. This grant gives Pluriomics the opportunity to advance cardiovascular drug discovery, in order to reduce the development length, costs and late stage attrition of novel drug candidates.

Pluristyx

Over the years, Pluriomics has implemented its Pluricyte® Cardiomyocytes and innovative technologies to provide high quality services for efficient and reliable safety pharmacology testing. Supported by 3.2 million euro SME instrument grant funding, Pluriomics will have the opportunity to further develop and improve their safety pharmacology assays as well as developing novel cardiac disease models and high-throughput screening assays for cardiovascular drug discovery.

“We are honored that the European Commission recognized the tremendous potential of our cardiomyocyte platform and Pluriomics as a disruptive business to invest in. The investment will accelerate growth of the company and market presence of Pluriomics products”, said CEO, Stefan Braam. “It will allow us to continue moving towards the market whilst significantly investing in new product development, screening and disease modeling capabilities.”

About Pluriomics

iPSC-derived cardiomyocte therapy

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics’ Pluricyte® Cardiomyocytes and innovative technologies are exceptionally well suited for implementation in various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing.

Pluriomics, with offices and research laboratories in Leiden, The Netherlands and production facilities in Gosselies, Belgium, was founded in 2010. For more information, please visit www.pluriomics.com.

About SME instrument grant

The SME instrument grant is part of Horizon 2020, which is the largest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020).

Provided with about €3 billion in funding over the period 2014-2020, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition. Available to SMEs only, which can organize a project in the way that best fits their business needs – meaning that subcontracting is not excluded – the new scheme has opened a new highway to innovation through phased, progressive and complimentary support.

For more information, please visit: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/sme-instrument.

Rate this post

Filed Under: iPS Cells, Stem Cells Tagged With: cardiomyocytes, drug discovery, iPSC, Pluriomics

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.